Rev­enue shrink­ing, Sanofi sweeps a PhII can­cer ADC and TB vac­cine pro­gram out of the pipeline in Q2 cleanup

A lit­tle more than a year ago Sanofi $SNY hand­ed Im­muno­Gen a $30 mil­lion pay­ment to gain ex­clu­sive de­vel­op­ment rights to a slate of ex­per­i­men­tal can­cer drugs in the pipeline, in­clud­ing the Phase II drug SAR566658, an ADC tar­get­ing CA6 spot­light­ed in the deal that was in de­vel­op­ment for triple neg­a­tive breast can­cer.

To­day, it’s his­to­ry.

The French phar­ma gi­ant wrote the drug off, say­ing that it was end­ing de­vel­op­ment ef­forts for the that drug as well as a TB vac­cine pro­gram.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.